Targeted Oncology2 天
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
The Pharma Letter2 天
FDA Breakthrough status for Trodelvy in ES-SCLC
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...
Daily20 小时
Gilead Sciences earns USFDA Breakthrough Therapy Designation for lung cancer treatment Trodelvy
Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...
腾讯网1 天
Trop-2靶向ADC再获突破性疗法认定，治疗难治性肺癌
01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...
Zacks.com on MSN1 天
GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...
Gilead gets FDA breakthrough therapy status for Trodelvy
Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
GSK’s lung cancer therapy gains EMA PRIME designation
GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...
腾讯网2 天
翰森制药(03692.HK)HS-20093获欧洲药品管理局优先药物认定
【财华社讯】翰森制药(03692.HK)公布，GSK就GSK5764227(GSK’227，亦称 ...
pharmaphorum5 天
NICE recommends Roche's Tecentriq in ES-SCLC following price rethink
ES-SCLC is a form of lung cancer accounting for one in eight lung cancer cases in the UK. It is an aggressive disease that progresses rapidly, with a significant negative impact on the quality of ...
FDA Grants Breakthrough Therapy Status To Gilead's Trodelvy For Treatment Of Small Cell ...
(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...